Financial Performance - Revenue for the year ended June 30, 2022, was HK$665,859,000, an increase of 8% from HK$616,361,000 in 2021[9] - EBITDA for the same period was HK$167,130,000, reflecting a 4% increase from HK$161,423,000 in 2021[10] - Profit attributable to owners of the company from continuing operations was HK$70,502,000, a 7% increase from HK$66,066,000 in 2021[10] - Total profit, including discontinued operations, was HK$72,168,000, representing a 107% increase from HK$34,834,000 in 2021[10] - Basic earnings per share increased to 9.34 HK cents, up 104% from 4.58 HK cents in 2021[10] - Proposed final dividend per share is 3.00 HK cents, a 7% increase from 2.80 HK cents in 2021[10] - Total revenue from continuing operations for FY2022 was approximately HK$665.9 million, representing an 8.0% increase compared to FY2021[26] - Profit attributable to owners of the Company for FY2022 was HK$72.2 million, reflecting an increase of over 100% compared to FY2021[26] - Basic EPS for FY2022 was HK$9.34, with a CAGR of 16.68% from FY2018 to FY2022[16] - Total revenue for the Group was HK$671.958 million, an increase of 7.9% from HK$622.765 million[98] Cash Flow and Assets - Cash and pledged deposits decreased by 20% to HK$238,120,000 from HK$295,867,000 in 2021[10] - Cash balance at the end of FY2022 was HK$295.9 million[17] - The Group's current assets were HK$432.8 million and current liabilities were HK$194.5 million, resulting in net current assets of HK$238.3 million and a current ratio of 2.23, indicating strong liquidity[128][129] - Cash and cash equivalents as of June 30, 2022, totaled HK$235.7 million, with no bank borrowings or outstanding loans[130][132] - The Group's gearing ratio was zero as of June 30, 2022, reflecting no net debt[133][134] Operational Highlights - The company has repositioned its presence in the PRC and continues to operate clinical and immigration medical exam services in Beijing and Shanghai[33] - Telemedicine services were offered since 2020, allowing patients to receive medical help during the pandemic[32] - The company administered COVID-19 vaccines at its medical clinics, supporting the Hong Kong government's vaccination efforts[31] - The company engaged in pandemic relief initiatives to support the community during the COVID-19 crisis[25] - The company reported a strong positive operating cash flow, enabling flexibility in growth despite economic challenges[37] - The company opened its first cardiometabolic center in Central and expanded its service area with a new multi-storey integrated medical center to attract high-end B2C market patients[38][42] - The UMP Network comprises approximately 1,000 points of services located across Hong Kong and Macau as of June 30, 2022[52] - The Group operates 12 advanced imaging and laboratory centers in Hong Kong, recognized by HOKLAS for quality[56] Market Strategy and Expansion - The company aims to broaden market shares in both B2B and B2C segments, focusing on value-based healthcare to cater to an aging population[40][43] - The COVID-19 pandemic accelerated the adoption of virtual care and digital engagement, with telemedicine now being a regular service offered[41][43] - The company is optimistic about resuming commuting for Greater Bay Area residents and plans to open new centers in prime districts to meet the demand for cross-border medical care[45][48] - Strategic relationships with medical groups, insurance companies, and hospitals have been established to enhance service referrals and network expansion[39][42] - The Group is actively exploring expansion opportunities to enhance its market position in the clinical imaging and laboratory business[78] Challenges and Risks - Revenue for Hong Kong & Macau Corporate Healthcare Solution Services increased by 2.0% from HK$232.4 million to HK$237.0 million, while operating profit decreased by 38.8% from HK$57.7 million to HK$35.3 million due to COVID-19 impacts[62] - Revenue for Hong Kong & Macau Clinical Healthcare Services rose by 11.4% from HK$449.3 million to HK$500.4 million, but operating profit fell by 14.9% from HK$80.6 million to HK$68.6 million, primarily due to increased operating expenses[68] - The Group continues to face challenges from COVID-19 variants but remains committed to upgrading its operating systems through technology investments[67] Investments and Acquisitions - The Group has invested in digitalization, creating a fully digital medical journey with self-invented electronic medical cards and claim vouchers to enhance service quality and reduce physical contact[67] - The Group acquired multi-service medical and treatment facilities in May 2022, enabling operations of day-surgeries, preventive health check-ups, and specialist consultations[72] - The acquisition includes state-of-the-art medical facilities suitable for day surgeries, preventive health check-ups, and vaccinations[78] - The Group's shareholding in UMP Healthcare China Limited decreased from 80% to 25% following the reorganisation, ceasing control over the company[93] Management and Leadership - Dr. Sun has over 45 years of experience in family medicine and is a founding fellow of the Hong Kong College of Family Physicians[172] - Ms. Kwok has over 25 years of experience in health schemes management and is responsible for overall management and business development of the Group[178] - Mr. Patrick Tsang has over 25 years of international capital markets experience and is responsible for strategic directions on cooperations with business stakeholders globally[184] - The Group's management team is focused on enhancing operational efficiency and expanding business activities[178] - The Group's directors include experienced professionals from various sectors, enhancing its strategic capabilities[184]

Expansion and Service Development - The Group expanded its flagship medical center in Central to two floors, with a gross floor area of approximately 27,000 sq. ft.[10] - The new medical centers include the Group's first cardiometabolic center and first UMP-branded physiotherapy and rehabilitation center, enhancing service offerings[10] - Service facilities in the flagship center have undergone expansion and renovation to meet changing community needs, providing enhanced access to services[11] - The company is expanding its one-stop health assessment services to cater to various groups and common health issues, including COVID-related assessments[19] - The company has expanded its professional medical team by recruiting additional experts in various specialties, including family medicine and radiology[17] Strategic Initiatives and Market Outlook - The strategic approach aims to cater to both B2B and emerging B2B2C markets, particularly in the Central district, while improving profitability and societal value[10] - The Group remains confident in the market outlook despite ongoing operational challenges due to the pandemic[10] - The new strategic initiatives reflect the Group's confidence in its business model and adaptability during challenging times[11] - The expansion of services aims to ensure sustainability and create value for society[10] - The operating environment is expected to remain challenging due to the ongoing pandemic and the rise of the Omicron variant, but healthcare awareness and demand are anticipated to grow[22] Financial Performance - Total revenue from continuing operations increased by 19.1% from HK$352.8 million in 2020 to HK$420.2 million in 2021[42] - Revenue for the corporate healthcare solutions business in Hong Kong and Macau increased by 1.8% from HK$122.3 million to HK$124.5 million, while operating profit decreased by 41.2% from HK$33.0 million to HK$19.4 million due to COVID-19 impacts[30] - Revenue for the medical, dental, and auxiliary services business line increased by 28.1% from HK$213.1 million to HK$273.0 million, with operating profit rising by 33.2% from HK$38.9 million to HK$51.8 million[31] - Profit for the period increased to HK$50,371,000 from HK$32,574,000, marking a significant rise of about 54.7%[166] - Total consolidated revenue increased by 19.7% from HK$299.2 million in 1HFY2021 to HK$358.2 million in 1HFY2022[46] Operational Metrics - The number of health check-ups contributed significantly to revenue growth across various segments[46] - The number of visits for corporate healthcare solution services increased by 20.0% from 408,427 in 2020 to 490,020 in 2021[64] - The number of medical visits rose by 20.6% from 395,260 in 2020 to 476,576 in 2021[64] - The Group's operational data for clinical healthcare services in Hong Kong and Macau showed a significant increase of 32.4% from HK$160.1 million in 2020 to HK$212.0 million in 2021[59] Shareholder and Governance Information - The Board declared an interim dividend of HK1.50 cents per ordinary share for the six months ended 31 December 2021, an increase from HK1.00 cent in FY2021[88] - The Company confirmed compliance with the Corporate Governance Code during the six months ended 31 December 2021, except for a deviation regarding the roles of chairman and CEO[93] - The Audit Committee reviewed the unaudited interim results for the six months ended 31 December 2021, confirming compliance with relevant accounting standards and legal requirements[104] - The company has adopted a standard code for the conduct of securities trading by directors, ensuring compliance and appropriate disclosures[105] Cash Flow and Financial Position - Cash flows from operating activities for the six months ended December 31, 2021, were positive, contributing to the overall financial stability of the company[176] - Cash and cash equivalents decreased to HK$259,410,000 from HK$293,974,000, a decline of approximately 11.8%[168] - Net cash flows from operating activities amounted to HK$35,128,000, a decrease from HK$46,053,000 in the previous period[177] - Total current liabilities decreased to HK$200,312,000 from HK$222,760,000, representing a reduction of approximately 10%[172] Compliance and Regulatory Matters - The company reported a legal reserve transfer of HK$23,000, demonstrating adherence to regulatory requirements[173] - The Group has extended the time limit for COVID-19-related rent concessions from June 30, 2021, to June 30, 2022, allowing previously ineligible concessions to be accounted for as negative variable lease payments[192] - The Group does not have contracts indexed to benchmark interest rates affected by the IBOR reform, thus the amendments to HKFRS do not impact the interim financial report[194] Future Growth and Market Strategy - The company aims to focus on growth opportunities in the Greater Bay Area in the future[27] - The company actively expands its business through acquisitions and opening new business units targeting emerging markets[27] - The company continues to operate conventional clinical and healthcare check-up businesses in Beijing and Shanghai[27]

Financial Performance - Revenue increased by 11.7% from HK$557.5 million in FY2020 to HK$622.8 million in FY2021, driven by strong growth in imaging and specialist lines of business[14] - Reported net profit decreased by 47.7% from HK$60.3 million in FY2020 to HK$31.5 million in FY2021, primarily due to one-off adjustments[14] - Adjusted EBITDA increased by 29.6% from HK$70.7 million in FY2020 to HK$91.7 million in FY2021, attributed to higher margin services[14] - Total revenue for FY2021 was HK$622.8 million, representing an increase of 11.7% compared to HK$557.5 million in FY2020[127] - Total operating profit increased to HK$73.6 million from HK$54.9 million[102] - Revenue for Hong Kong & Macau Clinical Healthcare Services increased by 21.9% from HK$368.7 million to HK$449.3 million[93] - Revenue for Mainland China Healthcare Business increased by 12.8% from HK$38.4 million to HK$43.3 million[94] - Revenue for Hong Kong & Macau Corporate Healthcare Solution Services decreased by 4.3% from HK$242.7 million to HK$232.4 million[88] - Operating profit for the same segment decreased by 26.1% from HK$52.0 million to HK$38.4 million[88] - The Group's clinical healthcare services revenue increased by 23.5% to HK$385.3 million in FY2021, up from HK$311.9 million in FY2020[127] Dividends and Shareholder Returns - The Board recommended a final dividend of HK2.8 cents per share, bringing the full year dividend to HK3.8 cents per share, up from HK3.3 cents per share in FY2020[14] - The company proposed a final dividend of HKD 0.028 per share, totaling HKD 0.038 per share for the year, up from HKD 0.033 per share in the previous fiscal year, pending shareholder approval[17] - The directors proposed a final dividend of HK$2.80 cents per share for FY2021, an increase from HK$2.65 cents per share in FY2020[174] - The proposed final dividend is expected to be distributed on January 26, 2022, to shareholders listed on the register as of December 10, 2021[174] Business Expansion and Strategic Initiatives - The company expanded online product offerings to include virtual care telemedicine services and same-day-delivery COVID-19 screening test kits[13] - Strategic goals include expanding the number of online and offline patient visits in Hong Kong, Macau, and Mainland China markets[15] - The company aims to transform its operations on a solid foundation to achieve its strategic goals[15] - The Group is expanding its flagship medical center in Central, Hong Kong, with a new leased floor of approximately 11,000 sq. ft. to provide specialized medical services[30] - A new health checkup center and a B2B2C business unit are being established in a renovated space of approximately 16,000 sq. ft. to meet growing demand in the post-COVID era[34] - The company is strategically expanding its medical network to untapped locations to enhance offline clinical services in rapidly growing population areas[35] - The company is actively exploring new mergers and acquisitions to broaden its advanced medical imaging and laboratory services, indicating a proactive growth strategy[42] - The Mainland China business is identified as a growth area, targeting opportunities driven by high demand for accessible and affordable healthcare services[55] Technological Advancements - The introduction of a fully-digital clinic visit experience with electronic medical cards and eVoucher devices marks a significant technological advancement in the company's service offerings[53] - The company has developed a patented eVoucher system for a fully digital consultation experience, enhancing operational efficiency and patient relationship management[56] - The implementation of a robust data management strategy has improved clinic operations efficiency and patient data management, enhancing patient relationship management[53] - The COVID-19 pandemic has accelerated the demand for online training and telemedicine services, creating new opportunities for the GOLD™ Training Programme[61] Healthcare Services and Market Demand - The aging population in Hong Kong is driving demand for comprehensive medical care, highlighting the need for expanded healthcare services[29] - The healthcare assessment division experienced rapid growth due to increased healthcare service demand in the post-pandemic era and immigration visa regulations, leading to a planned renovation of a 16,000 square feet space for general medical services[37] - The medical imaging and laboratory business achieved significant revenue growth of over 50% year-on-year, driven by the demand for advanced medical imaging services[40][43] - Axon Scanning Centre Limited, a wholly-owned subsidiary, reported over 70% revenue growth since its acquisition in FY2020, demonstrating strong performance in the medical imaging sector[42][44] Employee and Management Insights - A total of 20,686,000 share options were granted to senior management as part of a talent retention strategy, emphasizing the importance of strategic talent acquisition[23] - The Group had a total of 519 full-time employees, an increase from 452 in FY2020, with staff costs approximately HK$148.3 million compared to HK$140.9 million in FY2020[171] - The remuneration of directors is reviewed based on experience, responsibility, workload, and the Group's operating results[173] - The Group's employee remuneration policy ensures competitive pay levels and performance-related rewards[171] Financial Position and Risk Management - The financial position of the company remains healthy despite macroeconomic uncertainties[14] - Cash and cash equivalents as of June 30, 2021, were HK$294.0 million, with no bank borrowings or outstanding loans[140] - The Group's gearing ratio was not applicable as of June 30, 2021, as there was no net debt[142] - The group manages foreign currency risk primarily related to the Renminbi against Hong Kong dollars, without using derivative contracts for hedging[162][163] - Credit risk is managed by trading only with recognized and creditworthy third parties, with ongoing monitoring of receivable balances[164] Community Engagement and Corporate Social Responsibility - The establishment of the UMP Charity Foundation aims to improve medical care in Mainland China through training and clinical research collaborations[70] - The establishment of the United Medical Charity Foundation aims to enhance healthcare services in Mainland China through partnerships and training programs, utilizing the GOLD™ training courses[73] - The company is focusing on enhancing public engagement and patient empowerment through health education initiatives shared via its website and social media[56]

Revenue Performance - The Group recorded steady revenue performance for the six months ended December 31, 2020, despite the challenges posed by COVID-19[7]. - Total revenue for 1HFY2021 was HK$302.1 million, a decrease of 1.5% compared to HK$306.8 million in 1HFY2020[64]. - Revenue from Hong Kong & Macau Corporate Healthcare Solution Services decreased by 5.9% from HK$129.9 million to HK$122.3 million due to a general decrease in patient visits[37]. - Revenue from Hong Kong & Macau Clinical Healthcare Services increased approximately 5.7% from HK$201.6 million to HK$213.1 million due to an increase in health check-ups and average spending per visit[37]. - Revenue from PRC Healthcare Business decreased approximately 26.3% from HK$27.7 million to HK$20.4 million primarily due to a decrease in health check-ups as a result of COVID-19 travel restrictions[40]. - Revenue from corporate healthcare solution services to Contract Customers in Hong Kong and Macau decreased by 5.8% from HK$129.1 million in 1HFY2020 to HK$121.6 million in 1HFY2021[45]. - Revenue from Medical Services to Self-paid Patients increased by 9.2% from HK$121.5 million for 1HFY2020 to HK$132.7 million for 1HFY2021[48]. - Revenue from Dental Services to Self-paid Patients decreased by approximately 3.5% from HK$28.4 million for 1HFY2020 to HK$27.4 million for 1HFY2021[48]. - Other income and gains decreased by 65.1% from HK$10.9 million in 1HFY2020 to HK$3.8 million in 1HFY2021[48]. Business Adaptation and Services - The Group provided uninterrupted offline clinical services to outpatients and policyholders, demonstrating its extensive business network[8]. - The Group expanded its online product offerings, including same-day delivery of COVID-19 screening test kits, in response to rising demand during the pandemic[9]. - The Group's commitment to comprehensive medical services includes general and specialist services, regular health check-ups, medical imaging, laboratory services, dental services, physiotherapy, and cosmetic dermatology[8]. - The Group's agile business models allowed it to seize online business opportunities while maintaining social responsibility during the pandemic[9]. - The Group's healthcare solutions and tailor-made services have become increasingly relied upon by clients during social distancing measures[9]. - The company aims to deepen the integration of online and offline healthcare services to make healthcare more accessible and affordable[15]. - The remote consultation platform in China serves as a crucial portal for connecting family doctors with insured policyholders for on-demand consultations[16]. - The company engaged in various healthcare services, including corporate healthcare solutions and medical imaging, indicating a focus on expanding service offerings[200]. Technology and Innovation - The ongoing investment in technology has been validated by the increased public acceptance of medical technology due to COVID-19[7]. - The Group is poised to enhance service quality and market reach through continued investment in technology[7]. - The company continues to invest in people and technology for the rapid development of GOLD™ medical professional training and virtual care businesses in Mainland China, particularly in the Greater Bay Area[40]. - The company is committed to innovation as a key to sustained success in the growing Mainland China market[22]. Market Presence and Expansion - The Greater China network currently includes over 800 self-owned and affiliated medical service points across major cities, enhancing market presence[16]. - The company plans to open a new headquarters in Shenzhen with approximately 11,000 sq. feet of floor space to support training programs and capture business opportunities in the GBA[23]. - The establishment of 45 public-private partnership (PPP) clinics, with over 40 more planned, contributes to the company's status as one of the largest outpatient clinic networks in the GBA[21]. - The UMP Network comprises more than 800 service points across Hong Kong and Macau as of December 31, 2020[31]. - The company aims to provide comprehensive and affordable healthcare services through its well-established UMP Network[31]. - The company anticipates that the resumption of normal travel between Mainland China and Hong Kong will attract more visitors to its healthcare network and services[26]. Financial Performance - Profit for the period was HK$32,574,000, down 33.6% from HK$49,166,000 in the previous year[180]. - Basic earnings per share attributable to ordinary equity holders decreased to HK4.105 cents from HK6.046 cents, a decline of 32.2%[178]. - Total comprehensive income for the period was HK$33,936,000, compared to HK$37,185,000 in the prior year, reflecting a decrease of 8.4%[180]. - Cash generated from operations was HK$53,040,000, down 50.6% from HK$107,303,000 in the previous year[194]. - Net cash flows from operating activities amounted to HK$46,053,000, a decline of 56.3% compared to HK$105,271,000 in the prior period[194]. - Total current liabilities increased to HK$204,206,000 as of December 31, 2020, up from HK$159,775,000 on June 30, 2020, representing a 28% increase[185]. - Total non-current liabilities decreased to HK$49,248,000 from HK$61,025,000, reflecting a reduction of about 19%[185]. - Total equity attributable to owners of the company increased to HK$624,533,000 as of December 31, 2020, compared to HK$611,080,000 on June 30, 2020, marking a growth of approximately 2.3%[190]. Corporate Governance - The company is committed to high standards of corporate governance and has complied with the Corporate Governance Code, except for the separation of the roles of chairman and CEO[107][108]. - The Board consists of nine Directors, including six executive Directors and three independent non-executive Directors[110]. - The Audit Committee consists of three independent non-executive Directors, ensuring oversight and governance of the financial reporting process[117]. - The company has adopted a standard code for securities transactions by directors, ensuring compliance and ethical conduct in trading activities[118]. - The interim report reflects the company's commitment to transparency and adherence to regulatory standards in its financial reporting[119]. Shareholder Information - The Board declared an interim dividend of HK1.00 cent per ordinary share for the six months ended December 31, 2020, compared to HK0.65 cent for the interim dividend in FY2020[103]. - As of December 31, 2020, Dr. Sun Yiu Kwong held a total of 269,011,278 shares, representing approximately 35.13% of the company's shareholding[121]. - The company confirmed no incidents of non-compliance with the Code of Conduct for Securities Transactions by Employees during the six months ended December 31, 2020[116]. - The maximum number of shares to be issued under the Pre-IPO Share Option Scheme is 27,008,000, representing approximately 3.53% of the issued share capital as of December 31, 2020[134]. - The total number of shares held by Mr. Tsang On Yip was 2,600,000, representing approximately 0.34% of the company's shareholding[124].

Financial Performance - For the financial year ended June 30, 2020, UMP's revenue decreased by 1.7% to HK$557.5 million from HK$567.4 million in FY2019[20]. - Revenue for the fiscal year 2020 decreased by 1.7% to HK$557.5 million from HK$567.4 million in fiscal year 2019, primarily due to the impact of COVID-19 on patient visits, which dropped from 1.61 million to 1.35 million[22]. - Reported net profit increased by 208.5% from HK$19.5 million in FY2019 to HK$60.3 million in FY2020, despite macroeconomic uncertainties[24]. - Adjusted EBITDA decreased by 12.3% from HK$84.0 million in FY2019 to HK$73.7 million in FY2020, mainly due to reduced patient visits and increased investment in innovative technology[24]. - Total consolidated revenue decreased by 1.7% from HK$567.4 million in FY2019 to HK$557.5 million in FY2020, primarily due to a decrease in revenue from PRC healthcare services from HK$53.9 million to HK$38.4 million[141]. - Revenue for Hong Kong & Macau Corporate Healthcare Solutions decreased by 0.9% from HK$245.0 million to HK$242.7 million, while operating profit increased by approximately 30.5% from HK$39.8 million to HK$52.0 million[124]. - Revenue for Hong Kong & Macau Clinical Healthcare Services increased by 1.3% from HK$364.1 million to HK$368.7 million, but operating profit decreased by 21.3% from HK$46.1 million to HK$36.3 million[125]. - PRC Healthcare Business revenue dramatically decreased by 28.8% from HK$53.9 million to HK$38.4 million, with operating loss increasing by 796.1% from HK$3.7 million to HK$33.5 million[131]. Patient Visits and Services - Total patient visits declined from 1.61 million in FY2019 to 1.35 million in FY2020, primarily due to the impact of COVID-19[20]. - The number of visits for corporate healthcare solution services decreased from 1,315,686 in FY2019 to 1,106,304 in FY2020, a decline of 15.9%[166]. - The number of visits for clinical healthcare services decreased from 296,842 in FY2019 to 242,769 in FY2020, a decline of 18.2%[166]. Innovation and Technology - UMP launched Virtual Care telemedicine services and preferential COVID-19 screening test services to address community needs during the pandemic[18]. - Investment in innovative technology is a key focus, with plans to leverage artificial intelligence and deep learning in healthcare services[34]. - The company is committed to transforming traditional medical services by promoting modern technology and remote healthcare guidance[26]. - The company aims to address the shortage of premium healthcare resources through the expansion of online services[48]. - Virtual Care services have been expanded to cover various specialties, traditional Chinese medicine, and physiotherapy, maximizing technology application[112]. Strategic Goals and Expansion - The strategic goal for 2025 is to serve 30 million online and offline patient visits, expanding from the current 1.35 million visits[38]. - The strategic goal for 2025 is to expand user service from approximately 1.35 million to 30 million, including 3 million users in Hong Kong and Macau, and 27 million users in mainland China[39]. - The company aims to expand its market presence in the Greater Bay Area by collaborating with local institutions to enhance healthcare technology applications[25]. - The company aims to provide accessible, affordable, and trusted healthcare services in Greater China, establishing a sustainable primary healthcare model for all stakeholders[40]. Training and Development - The GOLD™ Training Programme has trained over 700 doctors and nurses from major cities in the Greater Bay Area, with expectations to exceed 1,000 by the end of 2020[56][57]. - The company has designed the GOLD™ Training Programme to improve consultation skills of community doctors, enhancing public trust in primary healthcare quality[54][58]. - The electronic training platform for the GOLD™ Training Programme provides real consultation cases as training materials, improving teaching quality for Mainland doctors[99]. - The design of the GOLD™ Training Base simulates a family doctor's office, improving interactive learning efficiency for General Practitioners[62]. Financial Health and Investments - The financial position of the group remains relatively healthy despite the challenges posed by the pandemic[24]. - The Group had cash and cash equivalents of HK$230.7 million as of June 30, 2020, with no bank borrowings or outstanding loans[173][174]. - The Group's gearing ratio was not applicable as of June 30, 2020, as there was no net debt[175]. - During FY2020, the Group incurred capital expenditure of approximately HK$26.8 million, an increase from HK$19.3 million in FY2019[192][197]. - The Group has a material capital commitment of approximately HK$16.5 million related to the acquisition of property, plant, and equipment as of June 30, 2020[194][199]. Operational Efficiency - The company adopted various measures such as streamlining workflow and automating processes through digitalization for better cost management[127]. - The upgraded service system offers convenient functions, significantly improving operational efficiency for corporate clients[83]. - The eVoucher system, launched in July 2019, has been applied to approximately 500 service points, improving operational efficiency and data accuracy for corporate clients[97]. Community Engagement and Healthcare Ecosystem - The company is committed to creating a healthcare ecosystem that integrates online and offline services, with expected benefits manifesting in the mid- to long-term[67]. - The company plans to hold more health education activities to enhance understanding of its one-stop healthcare solutions among clients and users[91]. - The company assists community health service centres in Mainland China to seek international accreditation by integrating Hong Kong's general practice standards into clinic design[105].

Business Performance - UMP Healthcare delivered over 1.6 million patient visits annually across Hong Kong, Macau, and Mainland China[9]. - The company achieved overall revenue growth across its business units, with significant growth in Adjusted EBITDA[9]. - Total revenue across all business lines increased by 15.7% from HK$310.5 million to HK$359.2 million[39]. - Revenue for Hong Kong & Macau Corporate Healthcare Solution Services increased by 7.1% from HK$121.3 million to HK$129.9 million, with operating profit rising approximately 17.5% from HK$16.1 million to HK$18.9 million[29]. - Revenue for Hong Kong & Macau Clinical Healthcare Services increased approximately 22.3% from HK$164.8 million to HK$201.6 million, while operating profit surged approximately 50.1% from HK$18.9 million to HK$28.3 million[30]. - Revenue for PRC Healthcare Business increased approximately 13.6% from HK$24.4 million to HK$27.7 million, although operating loss increased from HK$0.6 million to HK$2.6 million[37]. - Total consolidated revenue increased by 17.2% from HK$261.7 million in 1HFY2019 to HK$306.8 million in 1HFY2020[46]. - Revenue from corporate healthcare solution services to Contract Customers in Hong Kong and Macau increased by 7.1% from HK$120.6 million in 1HFY2019 to HK$129.1 million in 1HFY2020[46]. - Revenue from the provision of Medical Services to Self-paid Patients increased by 41.1% from HK$86.1 million for 1HFY2019 to HK$121.5 million for 1HFY2020[48]. - Revenue from Dental Services to Contract Customers increased by 36.3% from HK$9.1 million for 1HFY2019 to HK$12.4 million for 1HFY2020[46]. - Revenue from Dental Services to Self-paid Patients decreased by approximately 7.5% from HK$30.7 million for 1HFY2019 to HK$28.4 million for 1HFY2020[49]. Healthcare Services Expansion - UMP's GOLD™ program is now training over 200 doctors in Mainland China, focusing on the Greater Bay Area[12]. - The GBA public-private partnership clinic network has expanded to 30 outlets across major cities, making it one of the largest outpatient networks in the region[12]. - Plans are in place for the construction of additional PPP clinics in 2020[12]. - UMP launched a telemedicine platform in Mainland China, receiving positive feedback since its introduction in January 2020[12]. - UMP continues to invest in upgrading its services and technology to enhance patient experience[9]. - UMP is preparing to launch new premium healthcare services for non-corporate customers[9]. - The company is actively exploring partnerships with established healthcare groups to broaden its service offerings[9]. Financial Challenges and Outlook - UMP anticipates challenging operating conditions in the coming months, which may lead to negative financial performance in the short term[19]. - Despite a significant decrease in patient volume at offline clinics during the coronavirus outbreak, online consultation services have seen increased interest from customers[20]. - The company emphasizes the importance of continuous investment in technology to make healthcare more accessible and affordable[20]. - UMP is committed to innovation and bringing new solutions to patients and clients, regardless of the operating climate[20]. - The management acknowledges that any failures from trying new business initiatives are not fatal and will continue to adapt and innovate[21]. Employee and Operational Insights - The staff cost for 1HFY2020 was approximately HK$72.6 million, an increase from HK$67.3 million in 1HFY2019[115]. - The Group had a total of 429 full-time employees as of December 31, 2019, down from 456 as of June 30, 2019[115]. - Professional services expenses increased by 14.1% from HK$107.1 million for 1HFY2019 to HK$122.2 million for 1HFY2020[59]. - Property rental and related expenses decreased by 74.7% from HK$24.9 million for 1HFY2019 to HK$6.3 million for 1HFY2020[60]. - Depreciation and amortisation increased significantly from HK$9.9 million in 1HFY2019 to HK$35.4 million for 1HFY2020[61]. Shareholder Information - An interim dividend of HK$0.65 per ordinary share was declared for the six months ended December 31, 2019, consistent with the interim dividend of HK$0.65 per share for the same period in FY2018[124]. - The company has not exercised any share options under the pre-IPO share option scheme during the first half of the fiscal year 2020, with 27,008,000 options remaining unexercised as of December 31, 2019[120]. - The company granted 1,290,000 shares as part of its share award scheme during the first half of the fiscal year 2020[121]. - The company’s substantial shareholders include multiple entities with significant holdings, indicating a concentrated ownership structure[186]. - As of December 31, 2019, East Majestic Group Limited held 199,601,343 shares, representing 26.34% of the company's total issued share capital[186].

UMP HEALTHCARE HOLDINGS LIMITED (Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司) (Stock Code 股份代號: 722) Annual ##2019 CONTENTS 目錄 | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------|-------|-------| | | | | | | 2 | Corporate Information 公司資料 | | | | 4 | Chairman Statement 主席報告 | | | | 19 | Management Discussion and Analysis 管理層討論及分析 | | | | 36 | Biographical Details of Directors and Senior Management 董事及高級管理層履歷 | | | | 4 ...

Healthcare Vision and Strategy - The company aims to provide trusted and affordable healthcare services, emphasizing its vision to expand beyond the Hong Kong market into China[9]. - The company believes that its vision can contribute to solving healthcare problems in China and establishing trust between doctors and patients[11]. - The company has been focusing on the role of family doctors in delivering affordable and accessible care throughout its operations in China[18]. - The company is committed to tackling the root problems of the Chinese healthcare system, which is currently centered around specialist care[12]. - The company aims to attract like-minded individuals to join its vision for improving healthcare services in China[11]. - The company has made significant strides in promoting the family doctor model as part of China's healthcare reform[13]. Training and Development Programs - The company launched the General Practice Oriented Learning and Development programme (GOLD) in 2017 to train doctors in becoming well-rounded family doctors[19]. - The GOLD programme has gained accreditation from the Royal College of General Practitioners from the UK, symbolizing quality assurance in medical education[21]. - The GOLD programme aims to empower doctors with necessary skills and knowledge to enhance trust in family medicine, addressing the lack of trust in family doctors in China[22]. - The company emphasizes the importance of educating doctors to develop trust with patients through effective communication skills[19]. - The company is collaborating with regional governments to roll out its training programme, aiming to improve primary care services[30]. Financial Performance - Revenue for the Hong Kong & Macau Corporate Healthcare Solution Services increased by 12.1% from HK$108.2 million to HK$121.3 million, while operating profit decreased by 15.9% from HK$19.1 million to HK$16.1 million[36]. - Revenue for the Hong Kong & Macau Clinical Healthcare Services rose approximately 25.7% from HK$131.2 million to HK$164.8 million, with operating profit increasing approximately 67.9% from HK$11.2 million to HK$18.9 million[37]. - Revenue for the PRC Healthcare Business increased by 4.8% from HK$23.3 million to HK$24.4 million, while operating loss decreased by approximately 88.1% from HK$5.0 million to HK$0.6 million[38]. - Total consolidated revenue increased by 19.7% from HK$218.6 million in 1HFY2018 to HK$261.7 million in 1HFY2019[51]. - Revenue from corporate healthcare solution services to Contract Customers in Hong Kong and Macau increased by 11.9% from HK$107.8 million to HK$120.6 million[51]. - Revenue from Medical Services to Self-paid Patients increased by 42.5% from HK$60.4 million to HK$86.1 million[53]. - Revenue from Dental Services to Self-paid Patients increased by approximately 12.9% from HK$27.1 million to HK$30.7 million[54]. - Other income and gains increased by 130.5% from HK$5.9 million in 1HFY2018 to HK$13.6 million in 1HFY2019, primarily due to the gain on disposal of a subsidiary[56]. Cost and Expenses - Professional services expenses increased by 24.1% from HK$86.3 million in 1HFY2018 to HK$107.1 million in 1HFY2019, mainly due to higher costs of services rendered by healthcare professionals[62]. - Employee benefit expenses rose by 16.2% from HK$57.9 million in 1HFY2018 to HK$67.3 million in 1HFY2019, reflecting general increases in staff costs[63]. - Cost of inventories consumed increased by 16.1% from HK$11.2 million in 1HFY2018 to HK$13.0 million in 1HFY2019, in line with the increase in revenue from clinical healthcare services[67]. - Other expenses, net, surged by 295.5% from approximately HK$15.7 million in 1HFY2018 to HK$62.1 million in 1HFY2019, primarily due to a non-cash expense related to the issuance of Warrants[69]. Corporate Governance and Structure - The Company is committed to high standards of corporate governance and has complied with the Corporate Governance Code, except for the separation of roles of Chairman and CEO[113]. - The Company plans to continue reviewing its corporate governance structure and practices as deemed appropriate[115]. - The Board consists of nine Directors, including six executive Directors and three independent non-executive Directors[114]. - The Audit Committee reviewed the unaudited interim results for the six months ended December 31, 2018, confirming compliance with relevant accounting standards and legal requirements[123]. - The Company has adopted the Model Code for securities transactions, confirming compliance by all Directors during the six months ended December 31, 2018[120]. Share Options and Dividends - The Board declared an interim dividend of HK0.65 cent per ordinary share for the six months ended December 31, 2018, up from HK0.55 cent in FY2017[109]. - The company has a total of 27,608,000 options outstanding under the Pre-IPO Share Option Scheme, representing approximately 3.65% of the issued share capital as of December 31, 2018[145]. - The Post-IPO Share Option Scheme allows for a maximum issuance of 13,270,000 shares, which is about 1.75% of the issued share capital as of December 31, 2018[155]. - The Company adopted a Share Award Scheme on June 30, 2016, allowing a maximum of 1% of the issued share capital to be awarded to selected participants each year[168]. - A total of 5,910,000 shares were granted under the Share Award Scheme during the period, with none vested by December 31, 2018[173].